title: PPARγ in head and neck cancer prevention.
abstract: Head and neck cancer is a major source of morbidity and mortality worldwide. Intervention during the early phases of carcinogenesis represents a promising new strategy for curbing the devastating effects of this disease and its primary treatment modalities, surgery and radiation with or without concomitant chemotherapy. This review focuses on the peroxisome proliferator-activated receptor gamma (PPARγ) as a target for chemoprevention of oral cancer. Accumulating data suggest that ligands of PPARγ, which include the thiazolidinedione class of agents approved for the treatment of diabetes, inhibit cancer cell growth in vitro and in animal carcinogenesis models, providing the rationale for testing this approach in populations at risk for head and neck cancer.
authors.affiliation: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, United States.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Burotto
authors.affiliation: Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, United States. Electronic address: szaboe@mail.nih.gov.
authors.forename: Eva
authors.initials: E
authors.lastname: Szabo
mesh_terms: D002986:Clinical Trials as Topic; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D047495:PPAR gamma / Q000187:drug effects / Q000502:physiology*; D000077205:Pioglitazone; D011230:Precancerous Conditions / Q000473:pathology*; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone
keywords: Head and neck cancer; Oral carcinoma; PPARγ (peroxisome proliferator-activated receptor γ); Pioglitazone